Category: Market News

Moneysupermarket.com (LSE:MONY) posted steady financial results for the first half of 2025, with revenue edging up 1% to £225.3 million and adjusted EBITDA rising 2% to £75.1 million. The company marked key achievements, notably exceeding 1.5 million members in its SuperSaveClub, which now accounts for 14% of total group revenue. Despite facing headwinds in certain markets, Moneysupermarket.com continues to capitalize on its broad product range and ongoing investments in technology and data-driven innovations, including AI and new product launches. Additionally, the group declared a £96 million shareholder return package, underlining confidence in its strategic direction and growth outlook.

Financially, Moneysupermarket.com demonstrates strong cash flow and healthy margins. Technical indicators point to a stable market position, while its reasonable valuation and attractive dividend yield add appeal. The announced share buybacks further highlight management’s positive stance on the company’s future performance.

About Moneysupermarket.com

Moneysupermarket.com operates as a leading price comparison service in the financial sector, offering customers competitive options across insurance, financial products, home services, travel, and cashback. Its mission is to help consumers save money through transparent and efficient comparisons.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Hunting PLC (LSE:HTG) has secured a $31 million order to supply titanium stress joints for a deepwater gas development in the Black Sea. This award, combined with a previous contract, significantly boosts the company’s sales order backlog and supports its strategic ambition to grow within the expanding deepwater subsea market. The deal also leverages Hunting’s recent acquisition of Flexible Engineered Solutions, enhancing its capabilities in this sector.

The company’s outlook shows solid revenue expansion and a strong financial position, though profitability challenges and bearish technical signals temper the overall sentiment. Positive developments and a healthy dividend yield offer some confidence, despite valuation concerns indicated by a negative price-to-earnings ratio.

About Hunting PLC

Founded in 1874, Hunting PLC is a global precision engineering company specializing in high-quality manufactured equipment and services. Listed on the London Stock Exchange, it operates internationally with a presence in the UK, USA, China, and beyond. The business spans five key segments, focusing on areas including Subsea Technologies and Advanced Manufacturing.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Anglo Asian Mining (LSE:AAZ) has officially launched operations at its Demirli copper mine, becoming the company’s second new mine to begin production in 2025. This milestone advances Anglo Asian’s goal of establishing itself as a mid-tier copper producer. The Demirli site is projected to deliver around 4,000 tonnes of copper concentrate in 2025, with output expected to ramp up to 15,000 tonnes annually starting in 2026.

The project has completed comprehensive environmental and social impact assessments, reflecting the company’s commitment to responsible mining practices. To support operations, Anglo Asian has hired 150 new staff, further contributing to local employment and economic growth in the Karabakh region.

The commencement of production at Demirli marks a key step in Anglo Asian Mining’s expansion strategy, reinforcing its footprint in Azerbaijan’s mining sector.

About Anglo Asian Mining

Anglo Asian Mining plc is a producer of gold, copper, and silver, with a diverse portfolio of assets located in Azerbaijan. The company is focused on evolving into a multi-asset, mid-tier copper and gold producer by 2030, with copper anticipated to become the primary driver of growth. This strategy includes bringing several new mining projects, such as Gilar and Demirli, into commercial production.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Creo Medical Group (LSE:CREO) announced a 40% rise in core technology revenues for the first half of 2025, meeting management’s expectations and setting the stage for ongoing expansion. The company has improved operational efficiency, cutting costs and losses while bolstering its cash reserves. Recent regulatory approvals and new strategic partnerships, particularly in the US, are expected to accelerate the uptake of its advanced energy surgical products.

Strategic moves such as selling a 51% stake in Creo Medical Europe and divesting parts of its Chepstow facility aim to strengthen cash flow and simplify operations. The company remains confident in its growth trajectory and is dedicated to improving treatment options for patients with pre-cancerous and cancerous conditions globally.

Despite solid corporate developments, Creo Medical’s outlook is tempered by ongoing financial challenges and valuation concerns. Technical indicators currently show a neutral to slightly bearish trend, which impacts the overall assessment.

About Creo Medical

Creo Medical specializes in developing minimally invasive electrosurgical devices, focusing on enhancing patient care through innovative energy-based endoscopy. Its flagship CROMA technology, powered by Kamaptive, combines multiple energy modalities to enable precise and safer surgical interventions, offering less invasive and more cost-effective solutions in surgery and endoscopy.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Kromek Group plc (LSE:KMK) has secured a notable £1.7 million contract as part of the UK Government’s Radiological Nuclear Detection Framework, marking a key achievement in the company’s growth trajectory. This agreement includes the provision of the D3S-ID wearable radiation detectors and associated services, which are expected to contribute to increased revenues within Kromek’s CBRN Detection division.

The award highlights Kromek’s established position and expansion potential in the radiological and nuclear detection market, reinforcing its role in supporting national security efforts.

While the company benefits from positive corporate developments and encouraging technical signals, ongoing financial and profitability challenges continue to influence its overall outlook.

About Kromek Group plc

Kromek Group plc is a leading innovator in radiation and bio-detection technologies. Headquartered in County Durham, UK, with operations extending to the US, the company designs and manufactures advanced detector components for medical, industrial, and security applications. Kromek specializes in nuclear radiation detection solutions for homeland defense and security markets, and is actively developing bio-security products aimed at detecting airborne pathogens.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Primary Health Properties PLC (LSE:PHP) has reported the latest acceptance figures for its ongoing takeover bid for Assura Plc. As of July 18, 2025, the company has secured valid acceptances representing around 1.18% of Assura’s outstanding ordinary shares. PHP is encouraging remaining Assura shareholders to respond to the revised offer by the deadline of August 12, 2025.

This acquisition aligns with PHP’s strategic objective to broaden its footprint within the healthcare real estate sector, potentially strengthening its market position and creating enhanced growth opportunities for investors.

Financially, Primary Health Properties maintains a solid foundation with a strong equity base and no debt, supporting operational resilience. Technical indicators point to positive momentum, though the relatively high price-to-earnings ratio suggests caution on valuation. The company’s acquisition strategy, including the potential merger with Assura, is expected to bolster its portfolio quality and income streams. Recent earnings calls highlight growth prospects driven by rising rental income and effective asset management, despite some operational headwinds.

About Primary Health Properties PLC

Primary Health Properties is a UK and Ireland-based real estate investment trust (REIT) focused on owning and managing modern, purpose-built healthcare facilities. Its portfolio primarily serves general practitioners, health service providers, and other healthcare professionals, aiming to support the delivery of high-quality primary care.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Red Rock Resources Plc (LSE:RRR) has provided a status update on its ongoing arbitration case in the Democratic Republic of Congo, where it is awaiting a Supreme Court ruling that could validate its claim for $4.503 million against a former joint venture partner. Meanwhile, the company is adjusting payment schedules related to its Australian assets and expects to receive royalty revenues from its gold projects in Colombia. In the Ivory Coast, Red Rock is actively reviewing offers for its gold portfolio, which may attract a premium valuation.

Facing financial pressures, the company is pursuing strategies to stabilize its position, including potential asset disposals and equity fundraising efforts, all while awaiting the outcome of the DRC legal proceedings.

Red Rock’s shares have experienced downward pressure amid ongoing profitability challenges and negative cash flow. Although technical signals hint at possible future improvements, the company’s valuation remains weak, with a negative price-to-earnings ratio and no dividend payouts. The legal case in the DRC and recent equity issues underscore both potential opportunities and risks ahead.

About Red Rock Resources

Red Rock Resources Plc is a natural resources exploration and development company focused on gold, base metals, battery metals, and hydrocarbons. Its operations are primarily based in Africa and Australia, targeting projects with growth and value potential.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Defence Holdings PLC (LSE:ALRT), formerly operating as Guild Esports PLC, has officially pivoted from the esports arena to the defence technology sector in a sweeping strategic overhaul. The company completed the sale of its esports division to DCB Sports LLC, shedding over £2 million in liabilities and securing £100,000 in cash, thereby significantly improving its financial standing.

This transformation marks the launch of a five-year strategic roadmap aimed at establishing Defence Holdings as a leading force in AI-powered defence and security technologies. Backed by a recent £3.45 million capital raise, the company is now focused on developing and acquiring cutting-edge solutions in areas such as autonomous systems, secure communications, advanced sensors, and AI-driven analytics.

About Defence Holdings PLC

Based in London, Defence Holdings PLC is a publicly listed defence technology company serving the UK and European markets. The firm specializes in high-performance, next-generation systems designed to deliver operational advantages across all domains—land, sea, air, space, and cyber. Through a focus on AI innovation and strategic asset development, Defence Holdings is aiming to reshape the landscape of modern defence capabilities.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Mosman Oil and Gas Limited (LSE:MSMN) has announced progress at its Sagebrush helium project in Colorado, where it holds an 82.5% working interest. The company has engaged independent consultancy Sproule Incorporated to conduct a formal assessment of helium resources, aimed at verifying and refining Mosman’s internal estimates. In addition, the company is preparing to undertake a 3D seismic survey and extended production testing of the Sagebrush-1 well, collecting vital data to support future exploration and commercialization strategies.

These initiatives mark an important phase in de-risking the project and advancing it toward potential commercial development. The work is expected to be funded using Mosman’s existing cash reserves, reflecting its strategic commitment to helium as a core focus.

While the company faces financial headwinds, including profitability concerns and a weak valuation profile, recent technical indicators and corporate developments suggest potential for incremental progress. A shift in strategic focus toward helium and a strengthened equity position may help lay the groundwork for longer-term gains.

About Mosman Oil and Gas Limited

Mosman Oil and Gas is a dual-focused exploration and development company with operations in the United States and Australia. The company is involved in the search for and development of helium, hydrogen, and traditional hydrocarbon resources. With an emphasis on assets offering both near-term cash flow and long-term growth potential, Mosman continues to reposition itself toward emerging energy markets, particularly the helium sector.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Verici Dx Plc (LSE:VRCI) has announced plans to raise a minimum of £5 million through a combination of new share placements, a direct subscription from a U.S. investor, and a retail offering. The capital raise is aimed at supporting the commercial rollout of the company’s cutting-edge kidney transplant diagnostic tools, positioning Verici for accelerated growth and greater market penetration in the organ transplant sector.

The funds will enable the company to expand the reach of its core products, including its flagship Tutivia™ test, which supports early detection of acute rejection in kidney transplant patients and is covered under Medicare. Despite facing ongoing profitability challenges and weak technical indicators, Verici’s strategic fundraising signals a push toward long-term value creation and broader clinical adoption.

About Verici Dx Plc

Verici Dx is a UK-based clinical diagnostics company specializing in advanced blood-based testing for the organ transplant market. Focused primarily on kidney transplants, the company’s product suite addresses critical gaps in post-transplant care. Its next-generation diagnostic tools aim to improve patient outcomes through early and precise detection of immune responses. With a growing footprint in the U.S. and innovative technologies backed by clinical validation, Verici is working to transform transplant monitoring and management.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.